The construction and application of registry and follow-up database in hepatobiliary tumor patients
10.3760/cma.j.cn115610-20220129-00062
- VernacularTitle:肝胆肿瘤患者登记与随访数据库的构建与应用
- Author:
Hui ZHANG
1
;
Chenyu JIAO
;
Yongqian ZHU
;
Changxian LI
;
Yongxiang XIA
;
Xiangcheng LI
;
Xuehao WANG
;
Yang ZHAO
;
Jin LIU
Author Information
1. 南京医科大学第一附属医院肝胆中心，南京 210029
- Keywords:
Liver neoplasms;
Biliary tract neoplasms;
Bidirectional cohort study;
Quality control;
Database
- From:
Chinese Journal of Digestive Surgery
2022;21(2):307-312
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of hepatobiliary malignant tumor is characterized by the coexistence of multiple treatment methods and multiple disciplines. In order to evaluate the clinical efficacy of different treatment measures or multiple treatment combinations, and to promote the standardized development of comprehensive treatment patterns for hepatobiliary malignant tumor, the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University constructs the registry and follow-up database in hepatobiliary tumor patients based on the information-based platform of the hospital, which will help guide clinicians to make scientific decisions and improve the level of clinical diagnosis and treatment. This study describes the framework design, function modules, data acquisition process and quality control of the database of hepatobiliary malignant tumor. Based on the observational bidirectional cohort study design, the previous clinical data can be sorted to match the current database, on the other hand, the clinical data can be prospectively collected including basic information, admission evaluation, surgical information and postoperative situation, comprehensive treatment measures, regular reexaminations and long-term follow-up, etc. The data quality control system can be improved by formulating standardized operation procedures, regularly personnel training and full-process data management plans. This database will provide high-quality real-world data for clinicians, researchers, and guideline experts, and then provide high-level medical evidence for the standardized development of comprehensive treatment patterns of hepatobiliary malignancies.
